Kunikane, Eriko http://orcid.org/0000-0002-4742-9459
Orii, Yusuke
Inoue, Akiko
Inatani, Masaru http://orcid.org/0000-0003-0896-996X
Funding for this research was provided by:
Senju Phrmaceutical (JP)
Article History
Received: 19 June 2023
Accepted: 11 August 2023
First Online: 7 September 2023
Declarations
:
: Eriko Kunikane and Akiko Inoue are employees of Senju Pharmaceutical Co., Ltd. Masaru Inatani received financial support from Senju. Masaru Inatani received research grants from Senju, Santen, Kowa, Otsuka, Johnson & Johnson, Alcon, HOYA, Nidek and Chugai, and lecture fees from Senju, Santen, Kowa, Otsuka, Glaukos, Beyer, Johnson & Johnson, Viatris, Novartis, Alcon, HOYA, JFC, Chugai and Sando, which are not related to the present study.
: The Aiphagan study was approved by the Institutional Review Board of the University of Fukui, while the Aibeta and Ailamide studies were approved by the Certified Review Board of the University of Fukui. These previous studies complied with the tenets of the Declaration of Helsinki. Since the current study was a post hoc pooled analysis of data from previous studies, online registration as a clinical trial in Japan was not required.